Multiple Myeloma

Multiple Myeloma

bb2121: Is CAR T-Cell Therapy Moving to Myeloma?

Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of acute lymphocytic leukemia and non-Hodgkin lymphoma, and might now be poised to shake...

Multiple Myeloma Outcomes Differ Based on Socioeconomic Factors

Despite the gains made in improving treatment for and care of patients with multiple myeloma (MM), disparities persist based on race and socioeconomic status....

Doubling Down on Double Transplant for Myeloma: Updated Results from EMN02/H095

More than a year ago, at the 2016 ASH Annual Meeting, Michele Cavo, MD, from the Serágnoli Institute of Hematology at Bologna University School...

BCMA Antibody Drug Conjugate Active in Patients With Heavily Pretreated Myeloma

In a phase I study presented at the 2017 ASH Annual Meeting, 60 percent of patients with heavily-pretreated multiple myeloma (MM) responded to treatment...

Controversies in Myeloma: The Who, When, and Why of Treatment

The recent expansion of treatment options for patients with multiple myeloma (MM) has introduced new opportunities for redefining the goals of therapy. At the...

Previous Malignancy May Increase Risk of Subsequent Malignancy in Patients With Myeloma

A number of new treatments for patients with multiple myeloma (MM) have become available in recent years, enabling patients to live longer. Unfortunately, these...
WIB_icon

Early Phase Study of Selinexor With and Without Dexamethasone for Patients With Myeloma and...

According to results of a phase I study published in Blood, treatment with the XPO1 inhibitor selinexor and dexamethasone led to half of patients...

How I Treat in Brief: New Agents in Myeloma

This month, Philippe Moreau, MD, discusses the changing landscape of multiple myeloma (MM) therapeutics and options for treatment in frontline and relapsed settings. This material...

The Ins and Outs of Inclusion Criteria for Myeloma Clinical Trials

Clinical trial protocols often incorporate strict eligibility criteria to maximize reproducible, results with minimal risk to trial participants. Unfortunately, restricting a trial’s patient population...

Is MRD Testing Worthwhile in Myeloma?

With the clinically effective treatment regimens now available for myeloma, more patients can achieve deep and sustained responses. The ability to measure minimal residual...
Advertisement

Current Issue

July 2018 Bonus Mid-Year Edition

This bonus issue features a look at the most recent changes to Maintenance of Certification programs, highlights from recent hematology/oncology meetings, and more.